On April 9, 2025, Kiyoshi Tanigawa, our President and CEO, spoke at the CPHI Japan 2025 International Pharmaceutical Development Biopharma Seminar held at Tokyo Big Sight. During the event, he presented our drug discovery initiatives under the title, “Development of Rare Disease Therapeutics Using Novel Nucleic Acid Technology ‘Staple Oligomers’ – A New Modality for Controlling Protein Expression Levels.”
For more details, please refer to the program below :
https://www.cphijapan.com/wp/wp-content/uploads/CPHIJapan2025_eDM_JP.